ISAC XX Abstracts on Disc Presented by Purdue University Cytometry Laboratories

FOLLOW UP OF HIV-1 INFECTED PATIENTS RECEIVING PENTATHERAPY AND INTERLEUKINE 2 (IL2):CD8-CD28+, CD8-CD38+ AND CD4-CD62L BLOOD LYMPHOCYTE SUBPOPULATIONS

Martine Chouraqui, Emmanuel Delbeke, Alain Lafeuillade, Dominique Sansot, Arnold Zannier, Stephane Chadapaud C.H.I.T.S. 1208, Avenue Colonel Picot 83256 TOULON CEDEX Toulon, FRANCE

Abstract Number: 6857     Clinical Cytometry  –  Immunology and AIDS

Patients: Evolution of lymphocyte subsets was analysed in the blood of 10 HIV1-infected patients receiving: ZIDOVUDINE (AZT), 300 mg, bid; DIDANOSINE (ddi), 200 mg, bid; 3TC, 150 mg, bid; RITONAVIR, 400 mg, bid; SAQUINAVIR, 600 mg, bid; +/- IL2 (3 courses of sub-cutaneous IL2 (PROLEUKIN*) at 7.5 Mui, twice by day, for 5 consecutive days, 8 weeks apart). Methods: Lymphocytes from blood were analysed by flow cytometry (COULTRONICS XL) using following monoclonal antibodies: CD4, CD8 (COULTRONICS); CD4-CD62L, CD8-CD28, CD8-CD38 (BECTON-DICKINSON). Viral load (plasma HIV-1 RNA) was measured by use of the Amplicor Monitor kit (ROCHE DIAGNOSTICS), with a limit of detection of 20 copies/ml. Results: With pentatherapy+IL2, there was a significant increase in CD4+ cells. Among CD4+ cells, there was a significant elevation of CD62L+ cells (3 fold). Patients had increased expression of CD8-CD28 and a decreased expression of CD8-CD38 and changes were concomitant with a break down of viral load. These data may suggest that clinical amelioration, decrease of viral load, CD4 increase are concomittant with a best homing of CD4 lymphocytes and a decrease of CD8 T-cells activation. Elevation of rates of CD8-CD28 will be discussed.

Keywords: HIV-1 INFECTED PATIENTS; PENTATHERAPY AND INTERLEUKINE 2; LYMPHOCYTE SUBPOPULATIONS; CD8-CD28+, CD8-CD38+ AND CD4-CD62L